UCB SA (UCB.BR) Stock Fundamental Analysis
Europe - EBR:UCB - BE0003739530 - Common Stock
222.5 EUR
-15.1 (-6.36%)
Overall UCB gets a fundamental rating of 6 out of 10. We evaluated UCB against 53 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. UCB is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes UCB very considerable for growth investing!
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
In the past year UCB had a positive cash flow from operations.
UCB had positive earnings in each of the past 5 years.
In the past 5 years UCB always reported a positive cash flow from operatings.
1.2 Ratios
UCB has a better Return On Assets (7.75%) than 60.38% of its industry peers.
UCB has a Return On Equity of 13.76%. This is comparable to the rest of the industry: UCB outperforms 58.49% of its industry peers.
UCB's Return On Invested Capital of 11.63% is in line compared to the rest of the industry. UCB outperforms 58.49% of its industry peers.
The Average Return On Invested Capital over the past 3 years for UCB is significantly below the industry average of 14.46%.
The last Return On Invested Capital (11.63%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
Looking at the Profit Margin, with a value of 19.45%, UCB is in the better half of the industry, outperforming 73.58% of the companies in the same industry.
UCB's Profit Margin has been stable in the last couple of years.
UCB has a Operating Margin of 26.58%. This is in the better half of the industry: UCB outperforms 67.92% of its industry peers.
In the last couple of years the Operating Margin of UCB has declined.
UCB has a Gross Margin of 73.38%. This is in the better half of the industry: UCB outperforms 62.26% of its industry peers.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
UCB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, UCB has more shares outstanding
Compared to 1 year ago, UCB has an improved debt to assets ratio.
2.2 Solvency
UCB has an Altman-Z score of 4.90. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
UCB has a better Altman-Z score (4.90) than 73.58% of its industry peers.
UCB has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as UCB would need 2.43 years to pay back of all of its debts.
UCB's Debt to FCF ratio of 2.43 is fine compared to the rest of the industry. UCB outperforms 71.70% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that UCB is not too dependend on debt financing.
UCB's Debt to Equity ratio of 0.29 is fine compared to the rest of the industry. UCB outperforms 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 4.9 |
ROIC/WACC1.51
WACC7.68%
2.3 Liquidity
UCB has a Current Ratio of 1.35. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of UCB (1.35) is comparable to the rest of the industry.
A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Quick ratio of 1.01. This is comparable to the rest of the industry: UCB outperforms 58.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
The Earnings Per Share has been decreasing by -0.86% on average over the past years.
UCB shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.56%.
The Revenue has been growing slightly by 4.60% on average over the past years.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.31% yearly.
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.38% yearly.
EPS Next Y51.36%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EPS Next 5Y27.31%
Revenue Next Year22.68%
Revenue Next 2Y18.33%
Revenue Next 3Y16.89%
Revenue Next 5Y13.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 34.66, UCB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as UCB.
UCB is valuated rather expensively when we compare the Price/Earnings ratio to 26.11, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 22.46, the valuation of UCB can be described as rather expensive.
Based on the Price/Forward Earnings ratio, UCB is valued a bit more expensive than the industry average as 62.26% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.55, UCB is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.66 | ||
| Fwd PE | 22.46 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 62.26% of the companies listed in the same industry.
UCB's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.52 | ||
| EV/EBITDA | 17.81 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UCB has a very decent profitability rating, which may justify a higher PE ratio.
UCB's earnings are expected to grow with 36.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y41.05%
EPS Next 3Y36.7%
5. Dividend
5.1 Amount
With a yearly dividend of 0.41%, UCB is not a good candidate for dividend investing.
UCB's Dividend Yield is comparable with the industry average which is at 2.99.
With a Dividend Yield of 0.41, UCB pays less dividend than the S&P500 average, which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
UCB pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EBR:UCB (10/31/2025, 7:00:00 PM)
222.5
-15.1 (-6.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap43.28B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts79.2
Price Target252.28 (13.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.24%
PT rev (3m)16.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.66 | ||
| Fwd PE | 22.46 | ||
| P/S | 6.32 | ||
| P/FCF | 36.52 | ||
| P/OCF | 27.46 | ||
| P/B | 4.47 | ||
| P/tB | 39.81 | ||
| EV/EBITDA | 17.81 |
EPS(TTM)6.42
EY2.89%
EPS(NY)9.91
Fwd EY4.45%
FCF(TTM)6.09
FCFY2.74%
OCF(TTM)8.1
OCFY3.64%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.67
PEG (5Y)N/A
Graham Number84.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 4.9 |
F-Score9
WACC7.68%
ROIC/WACC1.51
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y51.36%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EPS Next 5Y27.31%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year22.68%
Revenue Next 2Y18.33%
Revenue Next 3Y16.89%
Revenue Next 5Y13.38%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year150.43%
EBIT Next 3Y58.09%
EBIT Next 5Y37.74%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%
UCB SA / UCB.BR FAQ
What is the fundamental rating for UCB stock?
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
What is the valuation status of UCB SA (UCB.BR) stock?
ChartMill assigns a valuation rating of 4 / 10 to UCB SA (UCB.BR). This can be considered as Fairly Valued.
Can you provide the profitability details for UCB SA?
UCB SA (UCB.BR) has a profitability rating of 6 / 10.
How financially healthy is UCB SA?
The financial health rating of UCB SA (UCB.BR) is 6 / 10.
How sustainable is the dividend of UCB SA (UCB.BR) stock?
The dividend rating of UCB SA (UCB.BR) is 3 / 10 and the dividend payout ratio is 19.82%.